Abstract

FOR BRITISH pharmaceutical chemists, the news in recent months has been grim. In February, GlaxoSmithKline revealed that it would end neuroscience research at its Harlow site. Some 380 scientific positions were set for elimination among roughly 1,000 overall job cuts. The next month, AstraZeneca dropped the boom on its Charnwood laboratories, announcing the loss of about 1,200 jobs, mostly in R&D. These downsizings follow Merck & Co.’s 2008 closure of its basic research labs in Terlings Park, which employed close to 300 researchers, and Roche’s earlier downsizing of facilities in Welwyn. Pfizer, meanwhile, has been quietly cutting back on staff at its storied Sandwich research labs, where Viagra and several other big sellers were discovered. In a position statement released last month, the London-based Royal Society of Chemistry estimated that several thousand U.K. jobs have been lost at large pharmaceutical companies over the past few years. Amid the carnage, though, one bright spot for British ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.